WallStSmart

Alvotech (ALVO)vsUnited Therapeutics Corporation (UTHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

United Therapeutics Corporation generates 538% more annual revenue ($3.15B vs $494.61M). UTHR leads profitability with a 41.6% profit margin vs -36.3%. UTHR earns a higher WallStSmart Score of 61/100 (C+).

ALVO

Avoid

16

out of 100

Grade: F

Growth: 4.7Profit: 3.0Value: 6.7Quality: 5.5
Piotroski: 2/9Altman Z: -1.02

UTHR

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 9.0Value: 6.0Quality: 7.8
Piotroski: 5/9Altman Z: 8.56
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALVOUndervalued (+72.3%)

Margin of Safety

+72.3%

Fair Value

$17.49

Current Price

$5.29

$12.20 discount

UndervaluedFair: $17.49Overvalued
UTHRUndervalued (+0.8%)

Margin of Safety

+0.8%

Fair Value

$479.95

Current Price

$497.11

$17.16 discount

UndervaluedFair: $479.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALVO1 strengths · Avg: 10.0/10
Debt/EquityHealth
-7.5810/10

Conservative balance sheet, low leverage

UTHR5 strengths · Avg: 9.4/10
Profit MarginProfitability
41.6%10/10

Keeps 42 of every $100 in revenue as profit

Operating MarginProfitability
42.2%10/10

Strong operational efficiency at 42.2%

Altman Z-ScoreHealth
8.5610/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
20.5%9/10

Every $100 of equity generates 20 in profit

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Areas to Watch

ALVO4 concerns · Avg: 2.8/10
Market CapQuality
$1.86B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Revenue GrowthGrowth
-38.9%2/10

Revenue declined 38.9%

UTHR2 concerns · Avg: 3.0/10
PEG RatioValuation
2.224/10

Expensive relative to growth rate

Revenue GrowthGrowth
-1.9%2/10

Revenue declined 1.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : ALVO

The strongest argument for ALVO centers on Debt/Equity.

Bull Case : UTHR

The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 41.6% and operating margin at 42.2%.

Bear Case : ALVO

The primary concerns for ALVO are Market Cap, Return on Equity, Piotroski F-Score.

Bear Case : UTHR

The primary concerns for UTHR are PEG Ratio, Revenue Growth.

Key Dynamics to Monitor

ALVO profiles as a turnaround stock while UTHR is a declining play — different risk/reward profiles.

UTHR carries more volatility with a beta of 0.56 — expect wider price swings.

UTHR is growing revenue faster at -1.9% — sustainability is the question.

UTHR generates stronger free cash flow (206M), providing more financial flexibility.

Bottom Line

UTHR scores higher overall (61/100 vs 16/100), backed by strong 41.6% margins. ALVO offers better value entry with a 72.3% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alvotech

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.

Visit Website →

United Therapeutics Corporation

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.

Visit Website →

Want to dig deeper into these stocks?